ACE-167

According to publicly available company and drug-database descriptions, ACE-167 is designed to instruct the testis to make its own testosterone instead of supplying exogenous hormone. The peptide is reported to comprise amino-acid sequences that act as 14-3-3-epsilon binding motifs, limiting the interaction between 14-3-3-epsilon and the voltage-dependent anion channel 1 (VDAC1) and thereby favoring mitochondrial cholesterol handling and steroid synthesis in Leydig cells.

Acesis BioMed has described ACE-167 as its lead candidate for hypogonadism, with stated interest in extending the platform to conditions linked to low testosterone such as metabolic syndrome, non-alcoholic fatty liver disease, prediabetes, type 2 diabetes, osteoporosis, and obesity. As of this writing the program is in preclinical, IND-enabling stages and has not entered clinical trials.

Because no peer-reviewed studies specific to ACE-167 could be located, the mechanistic and efficacy claims here derive from company communications and industry databases rather than independent validation. The compound is included for completeness and is available for research use only; readers should treat its purported activity as unverified. Notably, ACE-167 is an endocrine/steroidogenesis peptide and is not a nootropic or cognitive agent despite appearing in some research-peptide catalogs.

There is no human safety data at all; every observation comes from rats. Within those studies the tolerability signals were reassuring: testosterone rose only 2 to 3 fold on average (with occasional higher spikes by other routes), tracked LH, and self-corrected over long infusions as the hypothalamic-pituitary-gonadal axis reasserted control, which the authors described as an inherent safety guardrail against the kind of overshoot seen with exogenous testosterone. Estradiol, aldosterone, and corticosterone stayed near control values for the short peptides.

None of that guarantees human safety. Unknowns include immunogenicity of a repeatedly dosed peptide, effects on fertility and spermatogenesis over time, off-target steroidogenesis in the adrenal gland, and long-term consequences of chronically stimulating Leydig cells. Anyone considering vendor-sold ACE-167 should understand it has never been through a regulated human trial, purity and identity of research-chem material is unverified, and self-dosing a testosterone-raising agent without monitoring is not a benign experiment.

The lineage runs through Vassilios Papadopoulos's lab, first at McGill University and later at the University of Southern California School of Pharmacy. In 2012 the group mapped 14-3-3 adaptor proteins into the mitochondrial steroidogenic complex and identified 14-3-3 gamma and later 14-3-3 epsilon as regulators of STAR activity. In 2014 Aghazadeh and colleagues published in Molecular Therapy that a TAT-VDAC1 fusion peptide (TV159-172), which blocks the 14-3-3 epsilon to VDAC1 interaction, raised intratesticular and serum testosterone in rats, including in animals whose LH had been suppressed by a GnRH antagonist.

The team then whittled the active region down to the tetrapeptide RVTQ and built orally stable analogs, work reported by Martinez-Arguelles and colleagues in Frontiers in Endocrinology in 2023, where RdVTQ emerged as an oral lead. Acesis Biomed (later Acesis Holdings), co-founded by Papadopoulos and CEO Costas Karatzas, licensed the chemistry and advanced RdVTQ as ACE-167 through IND-enabling work, with a first-in-human Phase 1 for male hypogonadism projected to begin within roughly two years of its late-2025 fundraising. Planned later indications include Klinefelter syndrome, metabolic syndrome, non-alcoholic fatty liver disease, prediabetes, type 2 diabetes, osteoporosis, and obesity.

Among endocrinology researchers the underlying idea (disrupting the 14-3-3 epsilon brake on cholesterol import to coax endogenous testosterone) is regarded as a legitimate and clever line of work with a solid publication trail in respectable journals. The distinguishing claims are oral activity of a four-residue peptide and a self-limiting, LH-dependent effect that in principle avoids the testicular shutdown and infertility linked to exogenous testosterone.

Enthusiasm is tempered by the obvious gap: no human trials, so efficacy and safety in people are entirely unproven. In the research-chem and biohacker community ACE-167 has appeared as vendor-sold capsules with marketing that outruns the evidence, framing a preclinical rat molecule as a near-term testosterone therapy. The measured view is that it is genuinely interesting science at an early stage, not a validated treatment, and not something with an established human dose.